Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580810 · ClinicalTrials.gov registry record · NA
Black Church Treatment Study
A NA study of Alcohol Use Disorder, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 137
- Enrollment target
- 3
- Study locations
NCT04580810: Active NA study of Alcohol Use Disorder, sponsored by NYU Langone Health.
NCT04580810 is a NA study of Alcohol Use Disorder that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 137 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (58% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04580810, a NA study of Alcohol Use Disorder, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 137 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will conduct a randomized clinical trial comparing levels of treatment initiation, engagement, and alcohol outcomes for a novel treatment strategy (CBT4CBT delivered in the Black church) compared with traditional outpatient specialty addiction treatment for a large sample of Black adults with AUD. The purpose of this randomized clinical trial is to determine which setting (church or specialty clinic) (1) has better treatment initiation and retention rates and (2) better AUD outcomes as measured by percentage of days abstinent (PDA) (8 weeks, 3, 6 and 9 months follow up).
Primary Outcome
Rates of treatment initiation as measured by proportion of participants completing at least one session at the assigned site
Conditions Studied
Interventions
- BEHAVIORAL CBT4CBT in the Black Church
Study Locations (3)
Connecticut
- Beulah Heights First Pentecostal Church - New Haven
- Dixwell Ave Congregational United Church of Christ - New Haven
- The Substance Abuse Training Unit (SATU) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2026-08-18 |
| Phase | NA |
What the registry record for NCT04580810 still lists
NCT04580810 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which CBT4CBT in the Black Church is the first listed.
NCT04580810 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04580810 about?
NCT04580810 is a clinical study titled "Black Church Treatment Study". This study will conduct a randomized clinical trial comparing levels of treatment initiation, engagement, and alcohol outcomes for a novel treatment strategy (CBT4CBT delivered in the Black church) compared with traditional outpatient specialty addiction treatment for a large sample of Black adults ...
What is the current status of trial NCT04580810?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 137 participants. The study started on 2021-07-07. Estimated completion is 2026-08-18.
What conditions does trial NCT04580810 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT04580810?
The interventions under investigation include: CBT4CBT in the Black Church (BEHAVIORAL).
Who is sponsoring clinical trial NCT04580810?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04580810 being conducted?
This trial has 3 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04580810's enrollment target sits among peer trials
137 71st of 184 higher than 114 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI